These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 25012446)

  • 1. Improvements in quality of life with desvenlafaxine 50mg/d vs placebo in employed adults with major depressive disorder.
    Endicott J; Lam RW; Hsu MA; Fayyad R; Boucher M; Guico-Pabia CJ
    J Affect Disord; 2014 Sep; 166():307-14. PubMed ID: 25012446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BDNF, interleukin-6, and salivary cortisol levels in depressed patients treated with desvenlafaxine.
    Ninan PT; Shelton RC; Bao W; Guico-Pabia CJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():86-91. PubMed ID: 24096053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of metabolic syndrome and thyroid hormone on efficacy of desvenlafaxine 50 and 100 mg/d in major depressive disorder.
    McIntyre RS; Fayyad R; Mackell JA; Boucher M
    Curr Med Res Opin; 2016; 32(3):587-99. PubMed ID: 26709542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Symptomatic and functional improvement in employed depressed patients: a double-blind clinical trial of desvenlafaxine versus placebo.
    Dunlop BW; Reddy S; Yang L; Lubaczewski S; Focht K; Guico-Pabia CJ
    J Clin Psychopharmacol; 2011 Oct; 31(5):569-76. PubMed ID: 21869698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of desvenlafaxine 50 mg compared with placebo in patients with moderate or severe major depressive disorder: a pooled analysis of six randomized, double-blind, placebo-controlled studies.
    Papakostas GI; Culpepper L; Fayyad RS; Musgnung J; Guico-Pabia CJ
    Int Clin Psychopharmacol; 2013 Nov; 28(6):312-21. PubMed ID: 23881185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post hoc analysis of the efficacy and safety of desvenlafaxine 50 mg/day in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder.
    Kornstein SG; Clayton A; Bao W; Guico-Pabia CJ
    Menopause; 2014 Aug; 21(8):799-806. PubMed ID: 24448103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pooled analysis of the efficacy of desvenlafaxine for the treatment of major depressive disorder in perimenopausal and postmenopausal women.
    Kornstein SG; Clayton AH; Bao W; Guico-Pabia CJ
    J Womens Health (Larchmt); 2015 Apr; 24(4):281-90. PubMed ID: 25860107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of desvenlafaxine 25 and 50▒mg/day in a randomized, placebo-controlled study of depressed outpatients.
    Iwata N; Tourian KA; Hwang E; Mele L; Vialet C
    J Psychiatr Pract; 2013 Jan; 19(1):5-14. PubMed ID: 23334675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of desvenlafaxine 50 mg/day on a subpopulation of anxious/depressed patients: a pooled analysis of seven randomized, placebo-controlled studies.
    Kornstein SG; Guico-Pabia CJ; Fayyad RS
    Hum Psychopharmacol; 2014 Sep; 29(5):492-501. PubMed ID: 25196042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder.
    Liebowitz MR; Yeung PP; Entsuah R
    J Clin Psychiatry; 2007 Nov; 68(11):1663-72. PubMed ID: 18052559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of the effect of desvenlafaxine on anxiety symptoms associated with major depressive disorder: pooled data from 9 short-term, double-blind, placebo-controlled trials.
    Tourian KA; Jiang Q; Ninan PT
    CNS Spectr; 2010 Mar; 15(3):187-93. PubMed ID: 20414167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder.
    DeMartinis NA; Yeung PP; Entsuah R; Manley AL
    J Clin Psychiatry; 2007 May; 68(5):677-88. PubMed ID: 17503976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician.
    Reddy S; Kane C; Pitrosky B; Musgnung J; Ninan PT; Guico-Pabia CJ
    Curr Med Res Opin; 2010 Jan; 26(1):139-50. PubMed ID: 19919295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of functional improvement in employed adults with major depressive disorder treated with desvenlafaxine.
    Lam RW; Endicott J; Hsu MA; Fayyad R; Guico-Pabia C; Boucher M
    Int Clin Psychopharmacol; 2014 Sep; 29(5):239-51. PubMed ID: 24583567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder.
    Liebowitz MR; Manley AL; Padmanabhan SK; Ganguly R; Tummala R; Tourian KA
    Curr Med Res Opin; 2008 Jul; 24(7):1877-90. PubMed ID: 18507895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of depressive symptoms in patients with major depressive disorder treated with desvenlafaxine or placebo.
    Kornstein SG; Fava M; Jiang Q; Tourian KA
    Psychopharmacol Bull; 2009; 42(3):21-35. PubMed ID: 19752839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg/day in adult outpatients with major depressive disorder.
    Liebowitz MR; Tourian KA; Hwang E; Mele L;
    BMC Psychiatry; 2013 Mar; 13():94. PubMed ID: 23517291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An evaluation of sexual functioning in employed outpatients with major depressive disorder treated with desvenlafaxine 50 mg or placebo.
    Clayton AH; Reddy S; Focht K; Musgnung J; Fayyad R
    J Sex Med; 2013 Mar; 10(3):768-76. PubMed ID: 22905811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of desvenlafaxine 50 mg and 100 mg on energy and lassitude in patients with major depressive disorder: A pooled analysis.
    Lam RW; Wajsbrot DB; Meier E; Pappadopulos E; Mackell JA; Boucher M
    J Psychopharmacol; 2017 Sep; 31(9):1204-1214. PubMed ID: 28718346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.